APO-QUININE 200 mg
Natural health product licensed in Canada
- Licence holder
- Apotex Inc.
- NPN or DIN-HM
- 02254514
- Status
- Inactive licence
- Licence date
- 20 August 2008
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- DIN de transition
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Silicon dioxide colloïdal, Gélatine, cellulose, Stéarate de magnésium, Talc
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 3 Capsule | 3 Tous les jours |
| Enfants | Not specified | minimum: 1 Capsule ; maximum: 3 Capsule | 3 Tous les jours |
Uses authorised in Canada
Antimalarial.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
The usual therapeutic doses of quinine frequently induce symptoms of mild to moderate cinchonism (tinnitus, headache, impaired hearing, nausea, blurred vision) but these symptoms are seldom severe enough to necessitate cessation of treatment. Serious adverse effects are relatively rare; however, more marked symptoms of cinchonism such as vomiting, abdominal pain, diarrhea and vertigo, dysrhythmias and hypotension may develop. Reactions to continued or large doses include hot and flushed skin, fever, profuse sweating, asthma and angioedema. Ophthalmologic: Quinine can affect the retina and optic nerve, causing symptoms such as photophobia, night blindness, disturbed colour perception, blurred or double vision. Quinine's effect on the eye can occur in overdose or at therapeutic doses, and may or may not be reversible. Other reactions to continued or large doses include; amblyopia, scotomata, diplopia, mydriasis, spasm of the retinal vessels and in severe cases, optic atrophy. Cardiovasuclar: Conduction disturbances, ventricular tachycardia and anginal symptoms have occurred with prolonged quinine therapy in highly sensitive patients. Gastrointestinal: Nausea, vomiting, diarrhea and abdominal pain. Nausea and vomiting may be related to CNS effects of quinine. Hematologic: Thrombocytopenic purpura, leucopenia, pancytopenia, coagulopathy, hypoprothrombinemia and agranulocytosis have been reported. Massive hemolysis is a rare complication of quinine therapy. Hypersensitivity Reactions: cutaneous flushing , pruritus, scarlatiniform, maculopapular or urticarial skin eruptions, fever, facial edema, gastrointestinal distress, dyspnea, tinnitus and impairment of vision have been reported. Extreme flushing of the skin with intesnse, generalized pruritus is most common. Hemoglobinuria and asthma have been reported rarely. Endocrine: Hypoglycemia, which may be severe and recurrent, has been reported in some patients with severe malaria caused by P. falciparum who received quinine therapy, and there was some evidence that quinine-induced insulin secretion may have been one of several possible precipitating factors.
- Précautions et mises en garde
Quinine has quinidine-like activity; the same precautions should be taken with quinine as with quinidine in patients with atrial fibrillation. Advise patients to notify physician if cutaneous angiodematous, visual or auditory symptoms occur. If evidence of hemolysis appears, stop the drug immediately.
- Contre-indications
Quinine is contraindicated in patients who have a known hypersensitivity to the drug. Cross-sensitivity between quinine and quinidine may occur. Quinine should not be used in patients with G-6-PD deficiency; tinnitus; optic neuritis; myasthenia gravis (quinine may exacerbate muscle weakness due to its neuromuscular blocking effects); hypoglycaemia; pregnancy unless required to treat a severe, life-threatening chloroquine-resistant malaria infection in the mother; history of blackwater fever and thrombocytopenic purpura (associated with previous quinine ingestion.)
Source
Official Health Canada record, licence 02254514
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.